Screening for familial defective apolipoprotein B-100 with improved U937 monocyte proliferation assay

Clin Chem. 1994 Mar;40(3):395-9.

Abstract

Frostegård et al. (J Lipid Res 1990;31:37-44) demonstrated that the proliferation of the human monocyte cell line U937 is critically dependent on the uptake of low-density lipoprotein (LDL) via the apo B, E (LDL) receptor, a characteristic that was used to detect patients with familial defective apolipoprotein B-100 (FDB). Here we applied this principle to develop a simple and reproducible assay for the detection of patients with functionally defective LDL. We added serum to U937 cells in cholesterol-free incubation medium and determined the increase in cell number after a 72-h incubation at 37 degrees C by using an electronic cell counter. Sera from 10 normolipidemic individuals and from 34 patients with type IIa hyperlipoproteinemia stimulated the growth of U937 cells in proportion to the exogenous cholesterol concentration (r = 0.83, P < 0.001) and the LDL-cholesterol concentration (r = 0.81, P < 0.001). However, sera from 16 patients with FDB stimulated less cell proliferation than did sera from patients with type IIa hyperlipoproteinemia with equal LDL-cholesterol concentrations. With a 15% reduction in growth as the cutoff value, this test had a sensitivity and specificity for diagnosis of FDB of 87.5% and 100%, respectively. The improved U937 monocyte proliferation assay can be used for screening hypercholesterolemic patients to detect individuals with functionally defective LDL.

MeSH terms

  • Apolipoprotein B-100
  • Apolipoproteins B / genetics*
  • Apolipoproteins B / pharmacology
  • Cell Division / drug effects
  • Cell Line
  • Humans
  • Hyperlipoproteinemia Type II / blood*
  • Leukocyte Count
  • Lipoproteins, LDL / blood*
  • Lipoproteins, LDL / pharmacology
  • Monocytes / cytology*
  • Mutation*

Substances

  • Apolipoprotein B-100
  • Apolipoproteins B
  • Lipoproteins, LDL